Compare STIM & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | VANI |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 111.0M |
| IPO Year | 2018 | 2014 |
| Metric | STIM | VANI |
|---|---|---|
| Price | $2.34 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.00 | $3.83 |
| AVG Volume (30 Days) | ★ 1.1M | 172.9K |
| Earning Date | 11-04-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,776,000.00 | $4,000,000.00 |
| Revenue This Year | $8.63 | N/A |
| Revenue Next Year | $9.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.92 |
| 52 Week High | $3.44 | $1.66 |
| Indicator | STIM | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 47.02 |
| Support Level | $1.19 | $0.92 |
| Resistance Level | $2.31 | $1.23 |
| Average True Range (ATR) | 0.25 | 0.07 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 35.21 | 57.92 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.